Play Earnings CallPlay Earnings Call
Vertex Pharmaceuticals Incorporated (VRTX) Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDT
Company Participants
Susie Lisa – Senior Vice President of Investor Relations
Miroslava Minkova
Conference Call Participants
Eliana Merle – Barclays Bank PLC, Research Division
Presentation
Eliana Merle
Barclays Bank PLC, Research Division
Hi, everyone. I’m Ellie Merle, one of the biotech analysts here at Barclays. Very excited to have Vertex here with us to discuss a lot of exciting news this week with the povetacicept Phase III amongst a lot else going on in the pipeline. Joining us is Miroslava and Susie Lisa from the Investor Relations team. Thank you both so much for joining us.
Question-and-Answer Session
Eliana Merle
Barclays Bank PLC, Research Division
Maybe to kick it off before we jump right into pove after. But we’ve seen Vertex shift from being a cystic fibrosis biotech to a more diversified story across several verticals. Could you walk us through the strategy behind the efforts you’ve made so far and what’s coming on the horizon?
Susie Lisa
Senior Vice President of Investor Relations
Sure. Thanks, Ellie, and thanks for having us very much. Yes, it’s a really exciting time. We have long been proud of the work we’ve done in cystic fibrosis, but have also long had the goal to diversify our revenue base as well as the patient groups that we can address. And I think are very pleased with the progress that we have been making, all while maintaining the utmost diligence and care towards that CF patient community and continuing to move the bar forward there in terms of our ongoing ALYFTREK launch now, which is our fifth commercialized medicine as well as having a NextGen 3.0 family of therapies already in the clinic, and we can talk more about that if there’s time.
